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Purpose: To evaluate the intraocular pressure (IOP)-lowering effect of adding dorzolamide 
1.0%/timolol 0.5% fixed combination (DTFC) to prostaglandin analogs (PGAs) as monotherapy 
in patients with normal tension glaucoma.
Methods: A prospective, clinical, case-controlled study of patients with normal tension 
  glaucoma. Patients had been on a once-daily night dose of prostaglandins (PGs) as monotherapy 
and then received DTFC added to PGs for 8 weeks. The IOP was measured at 9 am, week 0 
(baseline), week 4, and week 8.
Results: The baseline IOP of 40 patients who had previously been treated by prostaglandin 
monotherapy was 15.6 ± 2.0 mmHg at baseline. The IOPs at 4 and 8 weeks after adding DTFC 
to PGs were 13.5 ± 2.1 mmHg and 13.7 ± 2.2 mmHg, respectively. Significant decrease of the 
IOP was observed at each time point of measurement as compared with the baseline IOP before 
adding DTFC (P = 0.01). The percent IOP reduction from the baseline IOP at week 4 and week 8 
was 13.5% ± 12.3% and 11.7% ± 13.1%, respectively. The percentage of patients who achieved 
10% or more IOP reduction from the baseline IOP at week 8 was 62.5%. The baseline IOP was 
significantly correlated with the percent IOP reduction at week 8 (P = 0.03, r = 0.34).
Conclusion: DTFC therapy added to PGAs as glaucoma monotherapy is effective in patients 
with normal tension glaucoma.
Keywords: IOP-lowering effect, prostaglandin, dorzolamide 1%/timolol 0.5% fixed combina-
tion, fixed combination, normal tension glaucoma
Introduction
Elevated intraocular pressure (IOP) is a known risk factor for glaucoma progression 
and reduction of IOP can prevent the progression of glaucomatous optic nerve dam-
age and maintain the visual field.1,2 Normal tension glaucoma (NTG) is a disease 
characterized by progression of glaucomatous disorders despite the maintenance of 
IOP within the normal range. Nonetheless, reduction of the IOP is also important in 
the treatment of NTG, and it has been reported that the target reduction rate of IOP 
should be set at 30%.1,2
Numerous reports have indicated that prostaglandin analog (PGA) therapies are 
effective in reducing IOP in NTG.3–12 However, since PGAs produce only approximately 
a 20% reduction of IOP,3–12 it is considered that the use of prostaglandin (PG) alone may 
be insufficient for obtaining the required 30% reduction of IOP,   according to the reports 
of the Collaborative Normal-Tension Glaucoma Study Group.1,2 The majority of patients 
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eventually require more than one medication to control their 
IOP. When IOP control is   inadequate with PGAs alone, 
the addition of one of several therapies, including carbonic 
anhydrase inhibitor, timolol maleate 0.5%, and fixed combi-
nation therapies, has been shown to provide additional IOP 
control.13–17 However, it is yet unclear which of these therapies 
are superior in IOP control.
Treatment that is inconvenient or causes undesirable 
side effects encourages nonadherence in patients with 
  glaucoma. By contrast, reducing the number of products and 
the number of required daily instillations increases patients’ 
adherence.18–21 In recent years, various fixed combinations 
have been introduced in the market. Combining two medica-
tions in one bottle may reduce the time required to administer 
drops, the frequency or total number of drops, and the number 
of medication bottles. Therefore, the combination formula-
tion may improve the rate of compliance and consequently 
improve IOP control.
There are many reports that have demonstrated the 
efficacy of these drugs in lowering the IOP in patients with 
primary open-angle glaucoma.13–17 However, there are no 
reports on the effect of the fixed combination of dorzolamide 
1.0%/timolol maleate 0.5% (DTFC) (Cosopt®; MDS/Santen, 
Tokyo/Osaka, Japan) in NTG patients. In addition, there are 
also no reports on the additional IOP-lowering effect of DTFC 
in NTG patients treated with PGAs.
Therefore, in this study, the additive IOP-lowering effect 
of DTFC on PGAs monotherapy as the first-line therapy in 
Japanese patients with NTG was investigated.
Patients and methods
This was a prospective, clinical, case-controlled study under-
taken from December 1, 2010 to May 30, 2011. The study 
followed the tenets of the Declaration of Helsinki and had the 
approval of the ethics committee of Mizoguchi Eye Clinic. 
Written informed consent was obtained from each patient 
before the start of the study.
Patients with NTG satisfying all of the following inclusion 
criteria were eligible for the study: (1) having had received 
PG as first-line glaucoma monotherapy; (2) in cases of bilat-
eral NTG, the eye with higher IOP or the more advanced eye 
was selected; (3) aged 40 years or over; (4) refractive error 
of more than –6 dpt; (5) no history of previous treatment of 
glaucoma.
The exclusion criteria were: (1) patients with exfo-
liation syndrome; (2) patients with diabetic retinopathy; 
(3)   refractive error of less than or equal to –6 dpt; (4) patients 
with a history of ocular trauma, ocular inflammatory disease, 
glaucoma surgery, vitrectomy, and laser trabeculoplasty; 
(5) patients with conjunctivitis, dry eye or periocular cutane-
ous disease, possibly affecting the results of the investigation; 
(6) currently pregnant or nursing women, or women consid-
ering pregnancy were also excluded, as were patients with a 
history of noncompliance, or patients who had participated 
in another therapeutic drug study within 1 month; (7) history 
of cerebrovascular and hepatic disease.
NTG was diagnosed when glaucoma hemifield test 
results were outside the normal limits; the standard devia-
tion had a P-value ,0.05; or there was a cluster of three 
points or more in the pattern of the deviation plot, in a 
single hemifield, with a P-value ,0.05, one of which had 
to have a P-value ,0.01 on the Humphrey Swedish Interac-
tive Thresholding   Algorithm 24-2 test (Humphrey Visual 
Field Analyzer, model 750, Humphrey Instruments, San 
Leandro, CA) and/or a nerve fiber layer defect combined 
with a corresponding optic disk change. In addition, the IOP 
measured by Goldmann applanation tonometer (Haag-Streit, 
Koniz, Switzerland) was consistently less than 21 mmHg. 
Gonioscopy excluded angle closure, rubeosis, and   secondary 
glaucoma.
Patients who had previously received PG as glaucoma 
monotherapy, and needed to receive additive medications on 
PGAs monotherapy because of inadequate IOP reduction, 
were enrolled in the study. Twenty-four eyes were given 
tafluprost 0.005% (TAPROS®; Santen Pharmaceutical Co 
Ltd, Osaka, Japan), ten eyes were given latanoprost 0.005% 
  (Xalatan®; Pfizer, Inc, New York, NY), and six eyes were 
given travoprost 0.004% (TRAVATANZ®, Alcon Labora-
tories Inc, Fort Worth, TX). Patients received PG at a dose 
of one drop every evening (9 pm) to the study eye. IOP 
at the start of the study served as the baseline IOP. Once-
daily administration (at 9 pm) of PG as monotherapy was 
  continued and DTFC was added twice daily (9 am and 9 pm) 
for 8 weeks after the baseline visit. All patients enrolled in 
the study underwent a comprehensive ocular examination, 
including measurement of best-corrected visual acuity, slit 
lamp examination, and biomicroscopic fundus examination. 
Static gonioscopy was performed using Goldmann 2-mirror 
lens (Haag-Streit) at the first visit or before cataract surgery. 
IOPs were measured three times at 9 am using a Goldman 
applanation tonometer. If the difference in IOP between any 
two of the three measurements was greater than 3 mmHg, 
the median value was used. If it was less than 3 mmHg, the 
mean value was used.
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Statistical analysis
Baseline and post-treatment values were compared by a 
one-way repeated-measures analysis of variance test. The 
difference in IOP was assessed by a paired t-test. Correlation 
between the baseline IOP and percent IOP reduction was ana-
lyzed by Spearman’s correlation coefficient by rank test.
A P-value of ,0.05 (two-tailed) was regarded as statis-
tically significant. Statistical analysis was performed using 
Statistical Analysis System (v 8; SAS Institute Inc, Tokyo, 
Japan) software.
Results
In total, 44 patients (44 test eyes) were enrolled in this study. 
One patient dropped out of the study prematurely because of 
change of residence and discontinued their visit to the clinic. 
In three patients, treatment was discontinued because of the 
development of conjunctival hyperemia and ocular irritation. 
After excluding these four cases, 40 patients were included 
in the final analysis.
The demographic features are summarized in Table 1. 
All patients were Japanese. The mean age was 69.8 ± 
12.0 years (range: 43–85 years). There were four males and 
36 females.
Table 2 shows the IOP and the percent IOP reduction 
from the baseline IOP at weeks 4 and 8. Significant decrease 
of the IOP was observed at weeks 4 and 8 as compared with 
the baseline IOP (P = 0.01). The percent reduction from 
the baseline IOP at weeks 4 and 8 was 13.5% ± 12.3% and 
11.7% ± 13.1%, respectively.
Table 3 shows the IOP and percent IOP reduction at each 
time point of measurement of the patient with a baseline IOP 
of 15 mmHg or higher (the high teens group) and those with 
a baseline IOP of less than 15 mmHg (the low teens group). 
In the high teens group, significant additional IOP reduction 
was observed at each time point of measurement as compared 
with the baseline IOP (P = 0.01). However, in the low teens 
group, there was no significant difference in the IOP from 
baseline IOP at any time point (P = 0.182). The percent reduc-
tion at week 8 from the baseline in the high teens group and 
the low teens group was 14.7% ± 11.7% and 6.6% ± 14.2%, 
respectively.
Tables 4 and 5 show the number and percentage of 
patients who achieved 10% or more, 20% or more, or 
30% or more IOP reduction from baseline at week 8. The 
  percentage of patients whose IOP reduction was 10% or more, 
20% or more, or 30% or more was 62.5%, 22.5%, and 5%, 
respectively (Table 4). In the high teens group and low teens 
group, those were 72% and 53%, 32% and 13%, and 8% and 
0%, respectively (Table 5).
Figure 1 shows the correlation between the baseline 
IOP and percent IOP reduction using Spearman’s correla-
tion   coefficient by rank test. The baseline IOP was signifi-
cantly correlated with the percent IOP reduction (P = 0.03, 
r = 0.34).
The most frequent adverse events related to the study 
medications were blurred vision, eye irritation, ocular 
Table 1 Demographic characteristics of the participants in the 
study
Number of subjects 40
Male/female 4/36
Eyes 40
Age (y) (mean ± SD) (range) 69.8 ± 12.0 (43–85)
RE (D) (mean ± SD) (range) -2.1 ± 3.5 (-6∼+2.5)
MD (dB) (mean ± SD) (range) -8.4 ± 0.37 (-24.5∼0)
IOL (eyes) 10
Previous therapy
  Tafluprost 24
  Latanoprost 10
  Travoprost 6
Abbreviations: RE, refractive error; MD, mean deviation; IOL, number of patients 
after cataract surgery; SD, standard deviation.
Table  2  The  mean  intraocular  pressure  (IOP)  and  percent 
reduction (%) at each time point from baseline IOP
Time Mean IOP (mmHg) (n = 40)
Baseline 15.6 ± 2.0
Week 4 13.5 ± 2.1*
Week 8 13.7 ± 2.2*
Percent reduction (%) in mean IOP from baseline
Week 4 13.5 ± 12.3
Week 8 11.7 ± 13.1
Note: *P = 0.01 vs baseline IOP, one-way repeated-measures analysis of variance.
Table  3  The  mean  intraocular  pressure  (IOP)  and  percent 
reduction  (%)  at  each  time  point  from  baseline  IOP  in  the 
subgroups
Time High teens group  
(n = 25)
Low teens group  
(n = 15)
Mean IOP (mmHg) Mean IOP (mmHg)
Baseline 16.8 ± 1.3 13.6 ± 0.9
Week 4 14.1 ± 2.1* 12.6 ± 1.8
Week 8 14.3 ± 2.1* 12.7 ± 2.1
Percent reduction (%) in mean IOP from baseline
Week 4 16.3 ± 10.7 7.6 ± 13.4
Week 8 14.7 ± 11.7 6.6 ± 14.2
Notes: High teens group: baseline IOP was 15 mmHg or more, Low teens group: 
baseline IOP was less than 15 mmHg. *P = 0.01 vs baseline IOP, one-way repeated-
measure analysis of variance.
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of the cases, DTFC have the capability to lower IOP even in 
patients with NTG. Thus, DTFC was found to have a favor-
able IOP-lowering effect. In addition, the drug   combination 
produced an approximate additional 13% lowering of the 
IOP, as compared with the baseline IOP, suggesting that 
the administration of DTFC can be expected to produce an 
additional effect in patients in whom the target reduction rate 
(30%) of IOP has not been achieved by administration of PG 
alone. Konstas et al15 have reported that the administration of 
latanoprost and DTFC had the strongest IOP-lowering effect 
in patients with primary open-angle glaucoma, suggesting 
that administration of the DTFC in addition to PG might also 
produce a strong IOP-lowering effect in patients with NTG. 
However, it was also found that the administration of DTFC 
had no significant IOP-lowering effect in patients with IOP 
levels of ,15 mmHg prior to the start of treatment, and no 
effect can be expected in such patients. The IOP was signifi-
cantly reduced after additional instillation in NTG patients 
with baseline IOP of .15 mmHg prior to the additional 
instillation, therefore, additional instillation is considered to 
be effective in NTG patients with relatively high IOP levels. 
In addition, a significant correlation was found between the 
baseline IOP prior to the additional instillation and the per-
cent IOP reduction from the baseline IOP; that is, the higher 
Table 4 The number of subjects who experienced a percentage 
decrease of intraocular pressure (IOP) at week 8 from baseline IOP
Percentage reduction after 8 weeks  
in mean IOP from baseline
No of subjects (%)
$10% 25 (62.5)
$20% 9 (22.5)
$30% 2 (5)
Table 5 The number of subjects who experienced a percentage 
decrease  of  intraocular  pressure  (IOP)  at  week  8  from  the 
baseline IOP in the subgroups
Percentage reduction  
after 8 weeks in mean  
IOP from baseline
High teens group  
(n = 25)
Low teens group  
(n = 15)
No of subjects (%) No of subjects (%)
$10% 18 (72) 8 (53)
$20% 8 (32) 2 (13)
$30% 2 (8) 0 (0)
Notes: High teens group: baseline IOP was 15 mmHg or more, Low teens group: 
baseline IOP was less than 15 mmHg.
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Figure 1 The correlation between the baseline intraocular pressure (IOP) and 
percent IOP reduction by using Spearman’s correlation coefficient by rank test.
Note: The baseline IOP was significantly correlated with the percent IOP reduction 
(P = 0.03, r = 0.34).
Table 6 Adverse events
Event Eyes (%)
Ocular hyperemia 1 (3%)
Eye irritation 3 (8%)
Eye itching 1 (3%)
Blurred vision 3 (8%)
hyperemia, and eye itching (Table 6). There were no systemic 
adverse events.
Discussion
A number of reports have indicated that DTFC might be 
effective in lowering the IOP in patients with glaucoma.13–17 
In addition, there are reports that the IOP-lowering effect of 
the dorzolamide/timolol fixed combination may be equivalent 
to that of concomitant dorzolamide/timolol therapy, and other 
reports suggesting that the fixed combination therapy has a 
significant IOP-lowering effect.14,16,17 All these studies were 
conducted in patients with primary open-angle glaucoma 
who have elevated IOPs. There have been no reports on the 
efficacy of DTFC in NTG patients, reported for the first 
time in this study. The reported IOP-lowering effect of PG 
is approximately 20% in NTG patients, which suggests that 
PGA alone is insufficient for obtaining the target 30% or more 
reduction of IOP,3–11 according to the report of the Collabora-
tive Normal-Tension Glaucoma Study Group.1,2 Glaucoma 
progression was seen significantly less frequently in the 
group in which a 30% or more IOP reduction was achieved, 
as compared with that in the group in which such reduction 
failed to be achieved.1,2 If the targeted IOP reduction can not 
be obtained with PGA monotherapy, additional medications 
are considered necessary. In this study, the IOP decreased 
significantly and remained low for 2 months with DTFC as 
second-line therapy, even in patients with NTG who had 
previously received IOP-lowering therapy with PGA. In 80% 
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IOP was prior to the start of the additional administration, 
the higher the percent IOP reduction from the baseline IOP. 
These results suggest that additional administration of DTFC 
is effective, and that it can improve the achievement rate of 
the target IOP in NTG patients, of which the targeted IOP 
could not be obtained with PGA monotherapy as first-line 
therapy.
It is considered important to determine the most effec-
tive PGs as the first-line medicine. If the target IOP cannot 
be achieved with PG monotherapy, additional instillation 
becomes necessary. It is reported that adherence to glau-
coma medication is often poor.18–20 Multiple factors related 
to poor adherence have been identified, including more 
frequent18 and complex dosing.20 Therefore, the number 
of medications should be reduced as much as possible for 
nonadherence patients. If IOP is inadequate with PGA as 
first-line medication, fixed combination should be added 
as second-line medication, because the therapy is less 
inconvenient.
With regard to safety, DTFC treatment is generally well 
tolerated. The most common adverse events in this study are 
eye irritation and blurred vision. All of the adverse events 
were mild. In this study, there was little change in the eyes 
after treatment compared with condition at the baseline 
period, suggesting that adverse events are unlikely to pose a 
significant clinical problem during use of DTFC.
Conclusion
This study suggests that a significant IOP-lowering effect 
can be obtained by instillation of DTFC in NTG patients in 
whom the target IOP has not been achieved by PG instil-
lation alone. Furthermore, the higher the IOP prior to the 
additional administration, the higher the rate of reduction of 
IOP became. Taking treatment adherence into consideration, 
it was considered that DTFC was useful as a second choice 
drug for use in elderly patients with NTG after treatment 
with a PG preparation. However, the number of cases in this 
study was small, and further studies with a larger number of 
cases are considered necessary.
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